KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Profit After Tax: 2018-2025

Historic Profit After Tax for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$31.3 million.

  • Esperion Therapeutics' Profit After Tax fell 6.13% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.8 million, marking a year-over-year decrease of 21.97%. This contributed to the annual value of -$51.7 million for FY2024, which is 75.27% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Profit After Tax is -$31.3 million, which was down 146.23% from -$12.7 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Profit After Tax registered a high of $61.0 million during Q1 2024, and its lowest value of -$90.9 million during Q1 2021.
  • For the 3-year period, Esperion Therapeutics' Profit After Tax averaged around -$31.4 million, with its median value being -$40.5 million (2025).
  • Its Profit After Tax has fluctuated over the past 5 years, first soared by 198.87% in 2024, then slumped by 166.30% in 2025.
  • Quarterly analysis of 5 years shows Esperion Therapeutics' Profit After Tax stood at -$65.1 million in 2021, then increased by 14.79% to -$55.5 million in 2022, then decreased by 1.54% to -$56.3 million in 2023, then soared by 62.16% to -$21.3 million in 2024, then decreased by 6.13% to -$31.3 million in 2025.
  • Its Profit After Tax was -$31.3 million in Q3 2025, compared to -$12.7 million in Q2 2025 and -$40.5 million in Q1 2025.